Jean-Christian Borel1, Renaud Tamisier2, Jesus Gonzalez-Bermejo3, Jean-Philippe Baguet4, Denis Monneret1, Nathalie Arnol2, Pascale Roux-Lombard5, Bernard Wuyam6, Patrick Levy2, Jean-Louis Pépin7. 1. INSERM 1042, HP2 Laboratory, Université Joseph Fourier, Faculté de Médecine, Grenoble. 2. INSERM 1042, HP2 Laboratory, Université Joseph Fourier, Faculté de Médecine, Grenoble; Pôle Rééducation et Physiologie, CHU, Hôpital A. Michallon, Grenoble. 3. AP-HP, Groupe hospitalier Pitié-Salpêtrière, Service de Pneumologie et réanimation médicale, Paris. 4. Département de cardiologie, CHU, Hôpital A. Michallon, Grenoble. 5. Service d'Immunologie et d'Allergologie, Hôpitaux Universitaires et Université de Genève, Geneva, Switzerland. 6. Pôle Rééducation et Physiologie, CHU, Hôpital A. Michallon, Grenoble. 7. INSERM 1042, HP2 Laboratory, Université Joseph Fourier, Faculté de Médecine, Grenoble; Pôle Rééducation et Physiologie, CHU, Hôpital A. Michallon, Grenoble. Electronic address: jpepin@chu-grenoble.fr.
Abstract
OBJECTIVE: Open studies suggest that treatment of obesity hypoventilation syndrome (OHS) by noninvasive ventilation (NIV) restores sleep quality and daytime vigilance and reduces cardiovascular morbidity. However, to our knowledge no randomized controlled trial (RCT) comparing NIV to conservative measures is available in the field. The goal of this study was to assess in patients with OHS, during an RCT, effects of 1-month NIV compared with lifestyle counseling on blood gas measurements, sleep quality, vigilance, and cardiovascular, metabolic, and inflammatory parameters. METHODS:Thirty-five patients in whom OHS was newly diagnosed were randomized either to the NIV group or the control group represented by lifestyle counseling. Assessments included blood gas levels, subjective daytime sleepiness, metabolic parameters, inflammatory (hsCRP, leptin, regulated upon activation normal T-cell express and secreted [RANTES], monocyte chemoattractant protein-1, IL-6, IL-8, tumor necrosis factor-α, resistin) and antiinflammatory (adiponectin, IL-1-RA) cytokines, sleep studies, endothelial function (reactive hyperemia measured by peripheral arterial tonometry [RH-PAT]), and arterial stiffness. RESULTS: Despite randomization, NIVgroup patients (n = 18) were older (58 ± 11 years vs 54 ± 6 years) with a higher baseline Paco(2) (47.9 ± 4.2 mm Hg vs 45.2 ± 3 mm Hg). In intention-to-treat analysis, compared with control group, NIV treatment significantly reduced daytime Paco(2) (difference between treatments: -3.5 mm Hg; 95% CI, -6.2 to -0.8) and apnea-hypopnea index (-40.3/h; 95% CI, -62.4 to -18.2). Sleep architecture was restored, although nonrespiratory microarousals increased (+9.4/h of sleep; 95% CI, 1.9-16.9), and daytime sleepiness was not completely normalized. Despite a dramatic improvement in sleep hypoxemia, glucidic and lipidic metabolism parameters as well as cytokine profiles did not vary significantly. Accordingly, neither RH-PAT (+0.02; 95% CI, -0.24 to 0.29) nor arterial stiffness (+0.22 m/s; 95% CI, -1.47 to 1.92) improved. CONCLUSIONS: One month of NIV treatment, although improving sleep and blood gas measurements dramatically, did not change inflammatory, metabolic, and cardiovascular markers. TRIAL REGISTRY: ClinicalTrials.gov; No.: NCT00603096; URL: www.clinicaltrials.gov.
RCT Entities:
OBJECTIVE: Open studies suggest that treatment of obesity hypoventilation syndrome (OHS) by noninvasive ventilation (NIV) restores sleep quality and daytime vigilance and reduces cardiovascular morbidity. However, to our knowledge no randomized controlled trial (RCT) comparing NIV to conservative measures is available in the field. The goal of this study was to assess in patients with OHS, during an RCT, effects of 1-month NIV compared with lifestyle counseling on blood gas measurements, sleep quality, vigilance, and cardiovascular, metabolic, and inflammatory parameters. METHODS: Thirty-five patients in whom OHS was newly diagnosed were randomized either to the NIV group or the control group represented by lifestyle counseling. Assessments included blood gas levels, subjective daytime sleepiness, metabolic parameters, inflammatory (hsCRP, leptin, regulated upon activation normal T-cell express and secreted [RANTES], monocyte chemoattractant protein-1, IL-6, IL-8, tumor necrosis factor-α, resistin) and antiinflammatory (adiponectin, IL-1-RA) cytokines, sleep studies, endothelial function (reactive hyperemia measured by peripheral arterial tonometry [RH-PAT]), and arterial stiffness. RESULTS: Despite randomization, NIV group patients (n = 18) were older (58 ± 11 years vs 54 ± 6 years) with a higher baseline Paco(2) (47.9 ± 4.2 mm Hg vs 45.2 ± 3 mm Hg). In intention-to-treat analysis, compared with control group, NIV treatment significantly reduced daytime Paco(2) (difference between treatments: -3.5 mm Hg; 95% CI, -6.2 to -0.8) and apnea-hypopnea index (-40.3/h; 95% CI, -62.4 to -18.2). Sleep architecture was restored, although nonrespiratory microarousals increased (+9.4/h of sleep; 95% CI, 1.9-16.9), and daytime sleepiness was not completely normalized. Despite a dramatic improvement in sleep hypoxemia, glucidic and lipidic metabolism parameters as well as cytokine profiles did not vary significantly. Accordingly, neither RH-PAT (+0.02; 95% CI, -0.24 to 0.29) nor arterial stiffness (+0.22 m/s; 95% CI, -1.47 to 1.92) improved. CONCLUSIONS: One month of NIV treatment, although improving sleep and blood gas measurements dramatically, did not change inflammatory, metabolic, and cardiovascular markers. TRIAL REGISTRY: ClinicalTrials.gov; No.: NCT00603096; URL: www.clinicaltrials.gov.
Authors: W Kinnear; L Watson; P Smith; L Johnson; S Burrows; J Colt; M Sovani; A Khanna Journal: Chron Respir Dis Date: 2016-12-06 Impact factor: 2.444
Authors: Habib Mohammad Reazaul Karim; Antonio M Esquinas; Sally Ziatabar; Giuseppe Insalaco; Szymon Skoczyński; Irena Šarc; Luigi Ferini-Strambi; Leyla Pur Özyiğit; Thierry Hernández-Gilsoul; Subrata Kumar Singha; Laura Ciobanu; José Luis Sandoval Gutiérrez; Zbigniew Szkulmowski; Edoardo Piervincenzi; Margarida Aguiar; Mohamad F El-Khatib; Nadia Corcione; Aslıhan Gürün Kaya; Aydın Çiledağ; Akın Kaya; Gabriele Valli; Paola Pierucci; Onofrio Resta; Paschalis Steiropoulos; Francesca De Marco; Vania Caldeira; Bushra A Mina Journal: Turk Thorac J Date: 2020-07
Authors: Juan F Masa; Jaime Corral; Auxiliadora Romero; Candela Caballero; Joaquin Terán-Santos; Maria L Alonso-Álvarez; Teresa Gomez-Garcia; Mónica González; Soledad López-Martínez; Pilar De Lucas; José M Marin; Sergi Marti; Trinidad Díaz-Cambriles; Eusebi Chiner; Miguel Merchan; Carlos Egea; Ana Obeso; Babak Mokhlesi Journal: J Clin Sleep Med Date: 2016-10-15 Impact factor: 4.062